Section I-C of the NIH Guidelines states that: 
The guidelines are applicable to all recombinant DNA research within the 
United States or its territories which is conducted at or sponsored by an 
Institution that receives any support for recombinant DNA research from 
the National Institutes of Health (NIH). 
Agracetus does not receive any support for recombinant DNA research from the 
NIH and therefore is not required to comply with the Guidelines. Section VI of the 
Guidelines, entitled "Voluntary Compliance" however encourages institutions "not 
otherwise covered by the Guidelines" to voluntarily comply. All submissions by 
Cetus Madison Corporation and Agracetus to the NIH which are discussed in this 
EA-FONSI were made voluntarily under Section VI of the Guidelines. Within 
Section VI of the Guidelines is a Section VI-E, entitled "Protection of Proprietary 
Data." Agracetus has indicated that material submitted to NIH contains 
"sensitive business information related to proprietary technologies." 
Environmental Assessment 
Page 8 
[ 478 ] 
